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Abstract 
BACKGROUND: Montelukast (Singulair) is a cysteinyl leukotriene receptor antagonist, used for the maintenance 
treatment of asthma and to relieve symptoms of seasonal allergic rhinitis and asthma, also used for exercise-
induced bronchospasm.  
AIM: This study was performed to determine the prevalence of Montelukast use as an add-on therapy among 
Iraqi asthmatic patients on treatment. Comparing the effectiveness of regimens with and without montelukast.  
METHODS: This descriptive cross-sectional study was carried out on 73 Iraqi asthmatic patients on treatment of 
both sexes with age range (18-60) years old, attending Al-Kindy Teaching Hospital and Al-Zahraa Centre of 
Asthma and Allergy, Baghdad, for the period between February and March 2017. A questionnaire was specifically 
prepared to meet the objectives and was used to collect the data of the study.  
RESULTS: There was a significant statistical reduction of frequency in asthmatic attacks after Montelukast 
treatment (p-value < 0.05). Out of 73 patients, 39 were males, and 34 were females, 46 were jobless, 37 were 
married, 63 were urban residents, 63 were educated. Prevalence of exacerbation factors was as following: 
infection was found in 60.3% of the patients, exercise in 57.5%, dust in 72.6%, smoking in 60.6%, food in 24.7%, 
others (stress, perfumes) in 20.5%. The prevalence of Montelukast use in this study was 46% (34 patients). Out of 
34 patients using Montelukast, 28 were using inhaled salbutamol, 5 were using oral salbutamol, 15 were using 
inhaled corticosteroids, 9 were using systematic corticosteroids, 2 were using xanthines, and 6 were using 
ketotifen.  
CONCLUSION: Montelukast was used as add-on therapy with the inhaled corticosteroids to reduce the required 
dose of inhaled corticosteroids also the use of Montelukast lead to reduced number of exacerbations which will be 
reflected on the use of inhaled salbutamol and systematic corticosteroids. Also, Montelukast was superior to 
xanthines and ketotifen as an add-on therapy. 
 
 
 
 
 
 
Introduction 
 
Asthma is defined as a chronic inflammatory 
disorder of the airways in which many cells and 
cellular elements play a role. In susceptible 
individuals, this inflammation causes recurrent 
episodes of wheezing, dyspnea, chest tightness, and 
coughing, especially at night or early morning [1]. An 
estimated 300 million people worldwide have asthma, 
with 250,000 annual deaths attributed to the disease 
[2]. This prevalence of asthma is expected to increase 
from 300 to 400 million by 2025 [3]. In Iraq, about 
200,000 patients per year with asthma are either 
hospitalised or treated in an emergency room. 
Prevalence of asthma in the adjacent countries to Iraq 
includes 5.6 % in Saudi Arabia and 8.5 % in Kuwait 
[4], [5]. 
The major etiologic factors of asthma are a 
genetic predisposition to type 1 hypersensitivity 
(atopy) and bronchial hyperresponsiveness to a 
variety of stimuli. In asthma, all cells of the airway are 
involved and become activated. Included are 
eosinophils, T cells, mast cells, macrophages, 
neutrophils, epithelial cells, fibroblasts, and bronchial 
smooth muscle cells [6]. Activation of these cells leads 
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to release of proinflammatory cytokines and mediators 
[7]. The risk factors for development of asthma include 
genetics, prenatal tobacco smoke (maternal smoking), 
prenatal diet and nutrition, prenatal antibiotic use 
(maternal use), mode of delivery, family size and the 
number and order of siblings, exposure to 
environmental tobacco smoke, socioeconomic status, 
viral infections and antibiotic use [8]. Also, there is 
asthma-related to workplace exposures [9].  
Montelukast (Singulair) is a cysteinyl 
leukotriene receptor antagonist used for the 
maintenance treatment of asthma and to relieve 
symptoms of seasonal allergies, also used for 
exercise-induced bronchospasm. It acts by blocking 
the action of leukotriene D4 (and secondary ligands, 
leukotrienes C4 and E4) on the cysteinyl leukotriene 
receptor 1 (Cys-LTR1) in the lungs and bronchial 
tubes by binding to it [10]. It is a controller drug that 
shouldn't be used for immediate bronchodilation. It is 
usually taken once a day with or without food.  
Corticosteroids effect is mediated by their 
ability to inhibit the production of inflammatory 
cytokines, potentiation of effects of B-agonists, but 
their most important action is inhibition of infiltration of 
asthmatic airways by lymphocytes, eosinophils, and 
mast cells [11]. The beta-2 adrenergic agonists are 
potent bronchodilators that are widely used in the 
management of bronchial asthma. These agents act 
by binding to the beta-2 adrenergic receptors on the 
smooth muscle of bronchial tissue, relieving 
bronchospasm and reducing airway resistance [12]. 
There are three important methylxanthines 
(theophylline, theobromine and caffeine). 
Methylxanthines act by inhibiting several members of 
phosphodiesterase family enzymes, especially PDE4. 
Inhibition of PDE4 results in higher concentration of 
cyclic adenosine monophosphate (CAMP). CAMP is 
responsible for relaxation of airway smooth muscle 
[13]. 
Ketotifen is a controller drug which inhibits the 
release and activity of mast cell and basophil 
mediators, including histamine, neutrophil, and 
eosinophil chemotactic factors, arachidonic acid 
metabolites (prostaglandins and leukotrienes) [14]. 
Oral ketotifen has been used in patients with asthma, 
allergic rhinitis, allergic conjunctivitis, atopic 
dermatitis. 
This study was performed to determine the 
prevalence of Montelukast use as an add-on therapy 
among Iraqi asthmatic patients on treatment 
comparing the effectiveness of regimens with and 
without montelukast.  
 
 
Material and Methods 
 
This descriptive cross-sectional study was 
carried out on 73 Iraqi asthmatic patients on treatment 
(patients taking Montelukast were included in the 
study), of both sexes with age range (34.18 ± 14.84), 
attending Al-Kindy Teaching Hospital and Al-Zahraa 
Centre of Asthma and Allergy, Baghdad, for the time 
period between February and March 2017. Patients 
were excluded if they have the pregnancy, metabolic 
disease, and psychiatric condition. The diagnosis of 
facial palsy was a clinical diagnosis done by an 
internal medicine specialist. After obtaining the formal 
approval from the Scientific and Ethical Committee in 
Al-Kindy College of Medicine, University of Baghdad, 
a questionnaire was specifically prepared to meet the 
objectives and was used to collect the data of the 
study. After obtaining verbal consent from each 
patient, an interview using the questionnaire was 
conducted. The data were prepared as frequencies, 
relative frequencies, charts, mean ± Standard 
deviation, Chi-square test and paired sample t-test 
were used for statistical analysis using SPSS program 
version 17. P-value < 0.05 was used as level of 
significance. 
 
 
Results 
 
Seventy-three patients participated in the 
study. Data from all of them were included in the 
analysis. 
Table 1 shows the number and percentage of 
asthmatic patients in each demographic characteristic 
like gender, occupation, marital status, address, and 
educational level.  
Males and females were nearly equal in 
number; jobless patients were more than patients who 
have a job, urban residents were much more than 
rural ones, married and unmarried patients are much 
nearly equal, educated patients were much more than 
non-educated ones. 
Table 1: No. of asthmatic patients in different demographic 
characteristics 
 Frequency 
Relative 
frequency (%) 
Gender 
Male 39 53.4 
Female 34 46.6 
Occupation  
Job 27 37 
Jobless 46 63 
Address 
Rural 10 13.7 
Urban 63 86.3 
Marital status 
Married 37 50.7 
Unmarried 36 49.3 
Educational level 
Educated 63 86.3 
Uneducated 10 13.7 
 
Table 2 shows the number and percentage of 
asthmatic patients in each age group. Age groups 
were (18-25), (26-40), (41-54), and (55-60) (years). 
The group which contained the largest number of 
patients was (18-25) years. The group which 
contained the least number of patients was (41-54) 
years. 
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Table 2: Number of asthmatic patients in different age groups 
(years) 
Age groups (years) Frequency Relative frequency (%) 
18-25 35 47.9 
26-40 15 20.5 
41-54 10 13.7 
55-60 13 17.8 
Total 73 100.0 
 
Table 3 shows the number and percentage of 
asthmatic patients in each disease duration category. 
Disease duration categories were, < 15 years, (16-30) 
years, (31-44) years, (45-58) years. Disease duration 
category which contained the largest number of 
asthmatics was (< 15 years). Disease duration 
category which contained the least number of 
asthmatics was (45-58) years. 
Table 3: Disease duration (years) and no. of asthmatic patients 
in each category 
Disease duration (years) Frequency Relative frequency (%) 
< 15 33 45.2 
16-30 26 35.6 
31-44 11 15.1 
45-58 3 4.1 
Total 73 100.0 
 
Figure 1 shows the percentage of asthmatic 
patients who have certain exacerbation factors like 
infection, exercise, dust, smoking, food and others 
(stress, perfumes). Most prevalent one was dust while 
the least prevalent factors were other factors (stress, 
perfumes). 
 
Figure 1: Prevalence of exacerbation factors 
 
Figure 2 shows the percentage of asthmatics 
who use Montelukast versus those who don't use it. 
 
Figure 2: Prevalence of Montelukast use among asthmatics 
 
Table 4 shows the number of asthmatics who 
use Montelukast in different age groups, versus those 
who don't use it. The age groups were (18-25), (26-
40), (41-54), (55-60) years.  
Table 4: Montelukast use in different age groups (years) 
Age groups (years) 
Montelukast use 
Total 
Yes No 
18-25 10 25 35 
26-40 6 4 10 
41-54 8 7 15 
55-60 10 3 13 
Total 34 39 73 
 
Table 5 shows the number and percentage of 
asthmatic patients who use certain drugs with 
Montelukast, also shows the number and percentage 
of asthmatics who don't use these drugs with 
Montelukast. Most of the patients used inhaled 
salbutamol with Montelukast. The very small 
percentage used xanthines with Montelukast. 
Table 5: No. of asthmatic patients using other drugs with 
Montelukast 
 Frequency Relative frequency (%) 
Inhaled salbutamol 
No 6 17.6 
Yes 28 82.4 
Oral salbutamol 
No 29 85.3 
Yes 5 14.7 
Systematic corticosteroids 
No 25 73.5 
Yes 9 26.5 
Inhaled corticosteroids (ICS) 
No 19 55.9 
Yes 15 44.1 
Xanthines 
No 32 94.1 
Yes 2 5.9 
Ketotifen 
No 28 82.4 
Yes 6 17.6 
 
Table 6 shows the mean of asthmatic 
attacks/month before Montelukast use and the mean 
of asthmatic attacks/month after Montelukast use. The 
asthmatic attacks/month were significantly reduced 
after Montelukast use, as p-value was < 0.05. 
Table 6: Comparison between the frequency of asthmatic 
attacks before and after Montelukast use in terms of means 
 mean of attacks/month 
Attacks/month before Montelukast use 6.47 ± 2.415 
Attacks/month after Montelukast use 2.29 ± 1.169 
 
 
 
Discussion 
 
In Table 1, most of this study asthmatics were 
living in urban areas, urban areas are known to have 
more industrialization and pollution, and this agrees 
with a study done by Hirshon J. et al., (2006), in which 
Maryland showed the highest rates of emergency 
department visits for asthma in urban areas [15].  
In Figure 1, the infection was an exacerbation 
factor in more than half of the asthmatics in this study, 
this agrees with a study done by K G Nicholson et al., 
(1993), in which it was concluded that respiratory 
infections especially viral infections are commonly 
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associated with asthmatic exacerbations [16]. Half of 
this study asthmatics were complaining from exercise 
as an exacerbation factor. Exercise-induced 
bronchospasm has been reported present in as few 
as 40% and as many as 90% of patients with asthma. 
In current study 34 patients were taking Montelukast, 
and Montelukast provided significant protection 
against exercise-induced bronchospasm as soon as 2 
hours after a single oral dose, with persistent benefit 
up to 24 hours [17]. Majority of this study asthmatics 
were complaining from dust as a triggering factor for 
asthmatic exacerbations, according to a study 
conducted by Woong Park, Hee Lim (2005), it was 
concluded that dust events impact on the respiratory 
symptoms of subjects with bronchial asthma, and 
ambient air pollution, particularly elevated particulate 
matter < 10 um in diameter, might be one of the 
aggravating factors [18]. Smoking was an 
exacerbation factor in more than half of the study 
asthmatics, A finding that agrees with a review 
conducted by Stapleton, Howard-Thompson (2011) 
In Table 5, the majority of asthmatics who use 
Montelukast were also using inhaled salbutamol, but a 
quarter of asthmatics who use Montelukast was not 
using inhaled salbutamol. According to a systematic 
review done by Zhang, Jia (2014), it was found that in 
comparison with placebo, adults with chronic asthma 
receiving Montelukast had significantly reduced 
number of exacerbations and this would be reflected 
on the use of inhaled salbutamol [20]. Only a small 
percentage of asthmatics were using oral salbutamol 
in addition to Montelukast, the difference in 
percentages between those using inhaled salbutamol 
and those using the oral one maybe due to the fact 
that oral salbutamol is less effective, having slower 
onset and more side effects than inhaled salbutamol 
[21]. More than half of the asthmatics using 
Montelukast, were not using inhaled corticosteroids. 
According to a study conducted by Andrew McIvor, 
Kaplan (2009), it was concluded that Montelukast is 
an effective alternative to inhaled corticosteroids in 
patients with mild asthma only. Others, who use 
Montelukast with inhaled corticosteroids, can use 
lower doses of inhaled corticosteroids in the presence 
of Montelukast. This agrees with previous studies, 
such as one performed by AL-Salami, Zaid (2011). 
Most of this study asthmatics using Montelukast, were 
not using xanthines, only very small percentage 
(5.9%) were using xanthines in addition to 
Montelukast. According to a study conducted by Shah 
(2004), it was concluded that the use of Montelukast 
along with inhaled bronchodilators and corticosteroids 
has a superior effect than addition of an oral sustained 
– release theophylline (a xanthine), on clinical and 
pulmonary function parameters in patients of chronic 
bronchial asthma [24]. Only a few asthmatics were 
using ketotifen with Montelukast (17.6%). According to 
a study performed by Al-Hamdani (2010), ketotifen 
and Montelukast were compared to each other and in 
conclusion, both ketotifen and Montelukast showed 
significant changes in asthma symptoms and 
pulmonary function tests after one month of treatment, 
but the changes were more significant with 
Montelukast group compared with ketotifen group and 
this indicated that Montelukast was more effective 
than ketotifen in treatment of asthmatic patients [25]. 
In Table 6, asthmatic attacks/month were 
significantly reduced after the use of Montelukast, this 
result agrees with a systematic review done by 
Miligkos, Bannuru (2015), in which it was found that 
the administration of Montelukast to adults and 
adolescents with asthma significantly reduced the risk 
of an exacerbation (asthmatic attack) and improved 
asthma control compared with placebo [26]. 
In conclusion, montelukast can be used as an 
add-on therapy with the inhaled corticosteroids to 
reduce the required dose of inhaled corticosteroids to 
reach the sufficient control, also the use of 
Montelukast lead to reduced number of exacerbations 
which will be reflected on the use of inhaled 
salbutamol and systematic corticosteroids. Also, 
Montelukast has a superior effect than xanthines and 
ketotifen as an add-on therapy.  
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